From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases
- PMID: 11260802
- PMCID: PMC1088427
- DOI: 10.1098/rstb.2000.0767
From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases
Abstract
The most common degenerative diseases of the human brain are characterized by the presence of abnormal filamentous inclusions in affected nerve cells and glial cells. These diseases can be grouped into two classes, based on the identity of the major proteinaceous components of the filamentous assemblies. The filaments are made of either the microtubule-associated protein tau or the protein alpha-synuclein. Importantly, the discovery of mutations in the tau gene in familial forms of frontotemporal dementia and of mutations in the alpha-synuclein gene in familial forms of Parkinson's disease has established that dysfunction of tau protein and alpha-synuclein can cause neurodegeneration.
Similar articles
-
Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1101-18. doi: 10.1098/rstb.1999.0466. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434313 Free PMC article. Review.
-
Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.Exp Neurol. 2004 Jun;187(2):279-88. doi: 10.1016/j.expneurol.2004.01.007. Exp Neurol. 2004. PMID: 15144854
-
Following the leader: fibrillization of alpha-synuclein and tau.Exp Neurol. 2004 Jun;187(2):235-9. doi: 10.1016/j.expneurol.2004.02.008. Exp Neurol. 2004. PMID: 15144849 Review. No abstract available.
-
alpha-Synuclein is phosphorylated in synucleinopathy lesions.Nat Cell Biol. 2002 Feb;4(2):160-4. doi: 10.1038/ncb748. Nat Cell Biol. 2002. PMID: 11813001
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
Cited by
-
Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders.J Neural Transm (Vienna). 2012 Dec;119(12):1551-60. doi: 10.1007/s00702-012-0838-3. Epub 2012 Jun 8. J Neural Transm (Vienna). 2012. PMID: 22678700 Free PMC article.
-
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.Acta Neuropathol. 2004 Sep;108(3):213-23. doi: 10.1007/s00401-004-0882-7. Epub 2004 May 28. Acta Neuropathol. 2004. PMID: 15170578 Free PMC article.
-
Cytosine beta-D-arabinofuranoside used as a paradigm modifier to increase production of tau aggregates in a cellular model of tauopathy.Neurochem Res. 2007 Apr-May;32(4-5):823-32. doi: 10.1007/s11064-006-9218-4. Epub 2006 Dec 6. Neurochem Res. 2007. PMID: 17151917
-
Extracellular Vesicle-Based Therapeutics in Neurological Disorders.Pharmaceutics. 2022 Nov 30;14(12):2652. doi: 10.3390/pharmaceutics14122652. Pharmaceutics. 2022. PMID: 36559145 Free PMC article. Review.
-
Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6. Mol Neurodegener. 2006. PMID: 16930453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous